By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

NHS advisors have again rejected pleas for potentially life-saving routine prostate cancer screening after concluding that ...

Screening with a PSA (prostate specific antigen) blood test reduces prostate cancer deaths by two for every 1000 men screened ...

Experts say prostate cancer remains a leading cause of cancer deaths in men. But new research at Yale shows that is likely to change. Dr. Nicholas Brutus, urology resident and lead author at the Yale ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

UK National Screening Committee rejects call from Olympic legend Sir Chris Hoy to offer PSA test to all men at higher risk of ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...